Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pyrazinamide + hydroxychloroquine
- Development stage
- Unknown
- Lead developer
- Saudi Arabia Ministry of Health
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This combination therapy, consisting of the anti-tuberculosis agent pyrazinamide and the antimalarial/immunomodulator hydroxychloroquine, is being developed by the Ministry of Health, Saudi Arabia, for the treatment of newly diagnosed drug-sensitive pulmonary tuberculosis. The regimen utilizes an AI-optimized dosing schedule (AIPH-TB framework) designed to maximize the synergistic interaction between the two drugs. Hydroxychloroquine acts as a synergistic adjuvant by inhibiting the BCRP-1 (ABCG2) efflux pump and raising phagolysosomal pH, which significantly increases the intracellular concentration and bactericidal activity of pyrazinamide against *Mycobacterium tuberculosis*. This approach aims to improve cure rates and reduce drug-induced hepatotoxicity compared to the standard four-drug RIPE regimen.
- Other names
- AI-Optimised Pyrazinamide / HydroxychloroquinePYZ-HCQ
02
Targets
ABCG2 (Breast cancer resistance protein)
Beyond the preview
Go deeper on pyrazinamide + hydroxychloroquine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pyrazinamide + hydroxychloroquine.